Evidence map›Paper›PMID 40636988›Full record

ArticleBJPsych open2025

Medicinal cannabis for tics in adolescents with Tourette syndrome.

Valsamma Eapen, Ping-I Lin, Kaitlyn Taylor, Eunice Chan, Paul Chay, Noel Cranswick, Amy Ka, Feroza Khan, Jonathan M Payne, Chidambaram Prakash and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJPsych open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Tourette syndrome.Nature reviews. Disease primers · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Valsamma EapenDiscipline of Psychiatry, School of Clinical Medicine and Health, University of New South Wales, Sydney, NSW, Australia.ORCID https://orcid.org/0000-0001-6296-8306
Ping-I LinDiscipline of Psychiatry, School of Clinical Medicine and Health, University of New South Wales, Sydney, NSW, Australia.
Kaitlyn TaylorCentre for Community Child Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Eunice ChanCentre for Community Child Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Paul ChayAcademic Unit of Child Psychiatry Southwest Sydney, South Western Sydney Local Health District and Ingham Institute, Sydney, NSW, Australia.
Noel CranswickCentre for Community Child Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Amy KaAcademic Unit of Child Psychiatry Southwest Sydney, South Western Sydney Local Health District and Ingham Institute, Sydney, NSW, Australia.
Feroza KhanDiscipline of Psychiatry, School of Clinical Medicine and Health, University of New South Wales, Sydney, NSW, Australia.
Jonathan M PayneCentre for Community Child Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Chidambaram PrakashDepartment of General Medicine, Royal Children's Hospital, Parkville, VIC, Australia.
Ramya VelalaganAcademic Unit of Child Psychiatry Southwest Sydney, South Western Sydney Local Health District and Ingham Institute, Sydney, NSW, Australia.
Daryl EfronCentre for Community Child Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medicinal cannabis has been trialled for Tourette syndrome in adults, but it has not been studied in adolescents. This open-label, single-arm trial study evaluated the feasibility, acceptability and signal of efficacy of medicinal cannabis in adolescents (12-18 years), using a Δ9-tetrahydrocannabinol:cannabidiol ratio of 10:15, with dose varying from 5 to 20 mg/day based on body weight and response. The study demonstrated feasibility of recruitment, acceptability of study procedures, potential benefits and a favourable safety profile, with no serious adverse events. Commonly reported adverse events were tiredness and drowsiness, followed by dry mouth. Statistically significant improvement was observed in parent and clinician reports on tics (paired

Indexed as

clinical trialsmedicinal cannabispaediatric neurologyTic disorderstics

Identifiers

PMID40636988
PMCPMC12247065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.